In a 12-month, open-label, randomized, controlled trial, combination therapy with leflunomide and glucocorticoids was superior to glucocorticoid monotherapy in preventing relapse of IgG4-related disease (IgG4-RD). Patients who received the combination therapy (n = 33) also had a shorter time to complete response and a longer duration of remission than those who received glucocorticoid monotherapy (n = 33). The combination therapy resulted in a lower cumulative dosage of glucocorticoids, suggesting that leflunomide could be used as a steroid-sparing agent in the management of IgG4-RD.
References
Original article
Wang, Y. et al. Additive effect of leflunomide and glucocorticoids compared with glucocorticoids monotherapy in preventing relapse of IgG4-related disease: a randomized clinical trial. Semin. Arthritis Rheum. https://doi.org/10.1016/j.semarthrit.2020.01.010 (2020)
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Onuora, S. Leflunomide plus glucocorticoids for IgG4-RD. Nat Rev Rheumatol 16, 186 (2020). https://doi.org/10.1038/s41584-020-0391-7
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41584-020-0391-7
